Raquel Campuzano Ruiz-rekin lankidetzan egindako argitalpenak (16)

2022

  1. Chronic coronary syndrome: practical management of antianginal drugs.

    Revista Espanola de Cardiologia Suplementos, Vol. 22, Núm. SE, pp. 1-10

  2. Comments on the 2021 ESC guidelines on cardiovascular disease prevention in clinical practice

    Revista Española de Cardiología (English Edition), Vol. 75, Núm. 5, pp. 364-369

  3. Comprehensive management of risk factors in peripheral vascular disease. Expert consensus

    Revista Clinica Espanola, Vol. 222, Núm. 2, pp. 82-90

  4. Knowledge of the clinical cardiologist on high-risk type 2 diabetes mellitus. What do we know and how can we improve?

    REC: CardioClinics, Vol. 57, Núm. 4, pp. 263-270

2021

  1. Comments on the 2020 ESC/EACTS guidelines for the management of atrial fibrillation

    Revista Espanola de Cardiologia, Vol. 74, Núm. 5, pp. 378-383

  2. Recomendaciones para mejorar el control lipídico en pacientes en prevención primaria. Documento de consenso de la Sociedad Española de Cardiología

    REC: CardioClinics, Vol. 56, Núm. 2, pp. 118-128

  3. Recommendations to improve lipid control in primary prevention patients. A consensus document of the Spanish Society of Cardiology

    REC: CardioClinics, Vol. 56, Núm. 3, pp. 208-217

  4. Recommendations to improve lipid control in primary prevention patients. A consensus document of the Spanish Society of Cardiology

    REC: CardioClinics, Vol. 56, Núm. 2, pp. 118-128

  5. Use of bempedoic acid in patients with dyslipidemia. A practical approach

    Revista Espanola de Cardiologia Suplementos, Vol. 21, Núm. SC, pp. 1-7

2018

  1. Comments on the 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases

    Revista espanola de cardiologia (English ed.), Vol. 71, Núm. 2, pp. 74-78

2006

  1. Effect of candesartan on coronary flow reserve in patients with systemic hypertension

    Journal of Hypertension, Vol. 24, Núm. 10, pp. 2109-2114

2004

  1. Determinación no invasiva del efecto de atorvastatina en la microvasculatura coronaria y la función endotelial perifé rica de pacientes dislipémicos

    Revista Espanola de Cardiologia, Vol. 57, Núm. 10, pp. 909-915

2002

  1. Aspirin in the primary prevention of the hypertensive patient

    Revista Clinica Espanola, Vol. 202, Núm. 12, pp. 652-654

  2. Prevención primaria con aspirina en la hipertensión arterial

    Revista Costarricense de Cardiología, Vol. 4, Núm. 2, pp. 36-41

  3. Serum basic fibroblast growth factor levels in exercise-induced myocardial ischemia more likely a marker of endothelial dysfunction than a marker of ischemia?

    European journal of medical research, Vol. 7, Núm. 3, pp. 93-97

  4. Tolerability and efficiency of new transdermic nitroglycerin patch in outpatients with chronic stable angina. The PATRICH Trial

    Revista Clinica Espanola, Vol. 202, Núm. 7, pp. 379-384